Zheng Quan Shi Bao Wang·2025-11-28 03:37Group 1 - The core project of Guanghua Pharmaceutical, "Children's Xiao Chai Hu Granules for treating pediatric gastrointestinal colds," has officially launched its Phase II clinical research in Tianjin, marking a significant step in traditional Chinese medicine for this indication [1] - This study is the first to apply the classic formula Xiao Chai Hu Decoction systematically for treating pediatric gastrointestinal colds, utilizing a randomized, double-blind, parallel-controlled modern evidence-based medical approach to explore the efficacy and safety of the treatment [1] - Currently, there are no similar products for children's Xiao Chai Hu Granules available in the market, indicating a potential gap in the market for pediatric proprietary Chinese medicine in this disease area [1] Group 2 - Guanghua Pharmaceutical has established multiple innovation platforms, including a doctoral workstation in Guangdong Province and a provincial enterprise technology center, and has applied for 22 core invention patents for its flagship product, Baiyunshan Xiao Chai Hu Granules [2] - The fingerprint detection method for Xiao Chai Hu Granules has been included in the 2025 edition of the Chinese Pharmacopoeia, showcasing the company's commitment to quality and innovation [2] - In response to a recent fire incident in Hong Kong, the company promptly mobilized resources and donated cash and materials worth 5 million HKD to support disaster relief efforts [2]